3FBIO Ltd.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

3FBIO Ltd. - overview

Established

2015

Location

Glasgow, -, UK

Primary Industry

Food

About

3FBIO Ltd. is a UK-based company specializing in the sustainable production of ABUNDA mycoprotein, utilizing a zero-waste fermentation process to create nutritious protein alternatives for food brands and retailers. Founded in 2015 in Glasgow, UK, 3FBIO Ltd. focuses on producing mycoprotein to meet the growing demand for sustainable food sources.


The company has successfully completed 7 funding deals, including a Series C round in February 2024, raising EUR 39. 60 mn from investors such as AXA Investment Managers, Cargill Inc. , and others, bringing total funding raised to EUR 39. 60 mn and a current valuation of EUR 172.


94 mn. The company is led by CEO Fernanda Meneguine and co-founders Craig Johnston, Jen Hansen, Romena Devyže, and Jim Laird. ENOUGH, a brand of 3FBIO, specializes in producing ABUNDA mycoprotein, which is created through a zero-waste fermentation process. This method yields a fibrous, meat-like texture that provides a complete protein source with all nine essential amino acids and is high in fiber.


ENOUGH targets retailers and food brands in Europe and North America, aiming to produce 1,000,000 tonnes of mycoprotein by 2032 as a contribution to sustainability in food production. In 2023, ENOUGH generated revenue of EUR 82,635. 40 from its B2B model, where clients purchase ABUNDA for incorporation into their product lines. The company operates on wholesale agreements, structured to meet the production scale and customer demands, focusing on bulk sales.


In February 2024, 3FBIO Ltd. secured Series C funding to enhance its global footprint. The company plans to expand its presence into new markets, particularly within Europe and North America, while further developing new products to meet evolving consumer demands. Recent funding will be allocated towards these expansion efforts, supporting the strategic aim of producing 1,000,000 tonnes of mycoprotein by 2032.


Current Investors

Coller Capital, DCVC, University of Strathclyde

Primary Industry

Food

Sub Industries

Other Food Products, Biomaterials

Website

www.enough-food.com

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.